MedPath

Balversa

Brand Name: Balversa

Generic Name: Erdafitinib

Active
Registration Number

DR-XY48332

Dosage Form

Film-Coated Tablet

Issuance Date

September 1, 2022

Expiry Date

September 1, 2027

Product Information

Philippine FDA product specifications and classification details

Product Specifications

Dosage Strength5 mg
PackagingPVC-PCTFE Foil Blister with an Aluminum Push through Foil in a Wallet Pack x 28's (Box of 28's)

Classification

C
Classification
Prescription Drug (RX)
P
Pharmacologic
Antineoplastic Agent [Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor]
A
Application
Monitored Release
Philippine FDA Classification

Active Ingredients (1)

Complete list of active ingredients in this pharmaceutical product.

ErdafitinibActive
Monograph: Erdafitinib

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Product

Company

Legal

© 2025 MedPath, Inc. All rights reserved.

MedPath - Medical Intelligence Platform